SNY Sanofi

42.91
-0.81  -2%
Previous Close 43.72
Open 42.5
Price To Book 1.64
Market Cap 107,310,795,608
Shares 2,500,834,202
Volume 2,294,811
Short Ratio
Av. Daily Volume 2,737,818
Stock charts supplied by TradingView

NewsSee all news

  1. Sanofi Pasteur and Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19

    The two companies will jointly investigate multiple candidates with the goal of advancing an efficacious and safe SARS-CoV-2 vaccine into clinical development PARIS and LEXINGTON, Mass., March 27, 2020 (GLOBE

  2. Sanofi successfully prices EUR 1.5 billion of bond issue

    Sanofi successfully prices EUR 1.5 billion of bond issue Paris, France – March 24, 2020 - Sanofi (NASDAQ:SNY) announces that it has successfully priced its offering of EUR 1.5 billion of notes (the "Notes") across 2

  3. Sanofi and Regeneron begin global Kevzara® (sarilumab) clinical trial program in patients with severe COVID-19

    CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 16, 2020 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc today announced they have started a clinical program evaluating Kevzara® (sarilumab) in patients hospitalized

  4. FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma

    BRIDGEWATER, N.J., March 2, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of

  5. Sanofi US reaches settlement agreement to resolve allegations related to patient assistance

    CAMBRIDGE, Mass., Feb. 28, 2020 /PRNewswire/ -- Sanofi U.S. today announced that it has reached an $11.85 million settlement agreement with the federal government to resolve an investigation relating to certain financial

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data presented at ASH December 10, 2019. Primary and secondary endpoints met.
Sutimlimab (BIVV009) - Cardinal
Cold agglutinin disease
FDA Approval announced September 28, 2018.
Cemiplimab
Cutaneous squamous cell carcinoma
Approval announced December 11, 2017.
Admelog (insulin lispro injection)
Diabetes
sBLA Approval announced April 25, 2017.
Praluent (alirocumab)
High low-density lipoprotein (LDL) cholesterol
Phase 3 trial commenced 4Q 2017. Seeking partner to take over and commercialize efpeglenatide.
Efpeglenatide
Type 2 diabetes
PDUFA date May 26, 2020.
Dupixent (dupilumab)
Atopic dermatitis 6-11 year-olds
FDA approval announced March 11, 2019.
Dupixent (dupilumab)
Atopic dermatitis 12-17 year-olds
FDA approval announced April 26, 2019.
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
FDA Approval announced March 2, 2020.
Isatuximab
Refractory Multiple Myeloma
Phase 3 data due 2Q 2020.
Avalglucosidase alfa (NeoGAA) - COMET
Pompe disease
FDA approval announced October 19, 2018.
Dupixent (dupilumab)
Asthma
Pivotal Phase 2/3 trial ongoing.
REGN2810
Cutaneous squamous cell carcinoma
Phase 3 interim analysis November 5, 2019 noted trial to continue as planned. Next interim look due 2020.
Cemiplimab
Non-small cell lung cancer (NSCLC)
Phase 3 data met two independent primary endpoints- January 30, 2020. Combination endpoint was not met.
Olipudase alfa
Acid sphingomyelinase deficiency (ASMD)
CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017.
Sarilumab
Rheumatoid arthritis
Phase 3 data due 4Q 2020.
Dupixent (dupilumab)
Asthma - 6-11 year-olds
FDA Approval announced June 26, 2019.
Dupixent (dupilumab)
Nasal polyps
Phase 2 data due 2020.
Dupixent (dupilumab)
Peanut Allergy
Phase 2 portion of Phase 2/3 trial due 2Q / 3Q 2020.
Dupixent (dupilumab)
Eosinophilic esophagitis
Approved under priority review - March 28, 2017.
Dupixent (dupilumab)
Atopic dermatitis
FDA Approval announced August 10, 2018.
Patisiran
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 3 enrolment ongoing - February 6, 2020.
Fitusiran (ATLAS)
Hemophilia
Approved January 23, 2019.
Fluzone Quadrivalent (Influenza Vaccine)
Influenza A - children 6-35 months of age.
Phase 2 data met primary endpoint - February 6, 2020. Data to be presented at upcoming meeting.
SAR442168 (PRN2246)
Multiple sclerosis
FDA approval announced May 1, 2019.
Dengvaxia
Dengue
FDA Approval announced February 6, 2019.
Caplacizumab
Acquired thrombotic thrombocytopenic purpura (aTTP)
Phase 2 data June 21, 2019 met primary endpoint vs placebo. No increased benefit compared to Dupixent.
SAR440340 (REGN3500)
Asthma
Phase 3 data due 2Q 2020.
Isatuximab - IKEMA
Refractory Multiple Myeloma
PDUFA date April 25, 2020.
MenQuadfi
Meningococcal meningitis
Phase 2 data due 3Q 2020.
SAR440340 / REGN3500
Atopic dermatitis
Phase 2 pivotal data due 1H 2020.
Cemiplimab
Basal cell carcinoma
Phase 1 biomarker data from first cohort to be presented 1H 2020.
THOR-707
Soild tumors
Phase 3 enrolment to be completed 2H 2020.
Cemiplimab
Non-small cell lung cancer (NSCLC)
Phase 2 data due 2H 2020.
SAR439859
Breast Cancer - third line
Phase 2/3 initiation announced March 16, 2020. Estimated primary completion date March 2021. U.S. trial.
Sarilumab
Coronavirus COVID-19
Phase 2/3 enrolment of global trial has been initiated - march 30, 2020.
Kevzara (sarilumab)
Coronavirus COVID-19

Latest News

  1. Sanofi Pasteur and Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19

    The two companies will jointly investigate multiple candidates with the goal of advancing an efficacious and safe SARS-CoV-2 vaccine into clinical development PARIS and LEXINGTON, Mass., March 27, 2020 (GLOBE

  2. Sanofi successfully prices EUR 1.5 billion of bond issue

    Sanofi successfully prices EUR 1.5 billion of bond issue Paris, France – March 24, 2020 - Sanofi (NASDAQ:SNY) announces that it has successfully priced its offering of EUR 1.5 billion of notes (the "Notes") across 2

  3. Sanofi and Regeneron begin global Kevzara® (sarilumab) clinical trial program in patients with severe COVID-19

    CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 16, 2020 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc today announced they have started a clinical program evaluating Kevzara® (sarilumab) in patients hospitalized

  4. FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma

    BRIDGEWATER, N.J., March 2, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of

  5. Sanofi US reaches settlement agreement to resolve allegations related to patient assistance

    CAMBRIDGE, Mass., Feb. 28, 2020 /PRNewswire/ -- Sanofi U.S. today announced that it has reached an $11.85 million settlement agreement with the federal government to resolve an investigation relating to certain financial

  6. Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine

    PARIS, Feb. 18, 2020 /PRNewswire/ -- Sanofi (NASDAQ:SNY, EURONEXT: SAN)) Pasteur, the vaccines global business unit of Sanofi, will leverage previous development work for a SARS vaccine which may unlock a fast path

  7. Sanofi delivers strong 2019 business EPS growth of 6.8% at CER

    PARIS, Feb. 6, 2020 /PRNewswire/ -- Sanofi (NASDAQ:SNY, EURONEXT: SAN)) Q4 2019 Change Change at CER 2019 Change Change at CER IFRS net sales reported €9,608m +6.8% +4.7% €36,126m +4.8% +2.8% IFRS net income

  8. Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency

    PARIS, Jan. 30, 2020 /PRNewswire/ -- Olipudase alfa, an investigational recombinant human acid sphingomyelinase, demonstrated positive results in two separate clinical trials evaluating olipudase alfa for the treatment

  9. Sanofi Completes Acquisition of Synthorx, Inc.

    PARIS, Jan. 23, 2020 /PRNewswire/ -- Sanofi (NASDAQ:SNY, EURONEXT: SAN)) announced today the successful completion of its acquisition of Synthorx, Inc. ("Synthorx") for $68 per share in cash. "The

  10. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  11. Sanofi awarded $226 million by US government to expand pandemic influenza preparedness

    SWIFTWATER, Pa., Dec. 9, 2019 /PRNewswire/ -- Sanofi Pasteur, the vaccines global business unit of Sanofi, has entered into an agreement with the U.S. Department of Health and Human Services (HHS) to increase the

  12. Pivotal data from Phase 3 study of sutimlimab in cold agglutinin disease to be presented at ASH 2019 late-breaking session

    CAMBRIDGE, Mass., Nov. 21, 2019 /PRNewswire/ -- Full data from the pivotal Phase 3 CARDINAL trial evaluating the safety and efficacy of sutimlimab in people with primary cold agglutinin disease (CAD) with a history of

  13. New data to be presented at ASH 2019 highlight Sanofi's commitment to treat challenging blood cancers and rare blood disorders

    CAMBRIDGE, Mass., Nov. 6, 2019 /PRNewswire/ -- New clinical data from Sanofi's oncology and rare blood disorders portfolios and pipelines will be featured, including four oral presentations and 18 posters, at the

  14. FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older

    PARIS, Nov. 4, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for use in adults 65 years

  15. Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes

    BRIDGEWATER, N.J., Nov. 4, 2019 /PRNewswire/ -- Children and adolescents (aged 6 to 17 years) living with type 1 diabetes achieved comparable reduction in average blood sugar (HbA1c) and similar risk of low blood sugar

  16. Sanofi Q3 well on track

    PARIS, Oct. 31, 2019 /PRNewswire/ -- Sanofi (NASDAQ:SNY, EURONEXT: SAN))  Q3 2019 Change Changeat CER 9M 2019 Change Changeat CER IFRS net sales reported €9,499m +1.1% -1.1% €26,518m +4.1% +2.2% IFRS net income

  17. Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing

    PARIS, Oct. 15, 2019 /PRNewswire/ -- Sanofi today celebrates the inauguration of its new digital manufacturing facility in Framingham, Massachusetts, marking one of the world's first digital facilities using

  18. New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer

    PARIS, Sept. 30, 2019 /PRNewswire/ -- Data published today in the New England Journal of Medicine showed that patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and

  19. Sanofi Canada receives Gold-Level Parity Certification

    Source: Sanofi (EURONEXT: SAN) (NASDAQ:SNY) First global biopharmaceutical company with a presence in Canada to be certified by Women in Governance LAVAL, QC, Sept. 26, 2019 /CNW Telbec/ - Sanofi Canada is pleased to

  20. Happify Health and Sanofi Sign Global Agreement to Bring Prescription Digital Mental Health Therapeutics to Individuals with Multiple Sclerosis

    NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Happify Health, a global leader in mental health technology, today announced it signed an agreement with global biopharmaceutical company Sanofi (NASDAQ:SNY) to advance the

  21. Hagens Berman: National Class-Action Lawsuit Accuses Sanofi of Concealing Zantac Cancer Risk

    Law firm urges Zantac users to find out their rights against drug maker who knowingly sold potentially carcinogenic medication A newly filed class-action lawsuit accuses international drug maker Sanofi of intentionally